How to Combined therapy?

Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

Hiro

939 results about "Combined therapy" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Combined therapy (kŏm-bynd) n. therapy that combines several types of treatment in order to improve results. It is usually a combination of surgery with radiotherapy and/or chemotherapy for the treatment of malignant tumours (see adjuvant therapy).

Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma

InactiveUS20020012665A1Avoiding and decreasing and resistanceOrganic active ingredientsIn-vivo radioactive preparationsFactor iiBiological activation

The present invention discloses combined therapies for treating hematologic malignancies, including B cell lymphomas and leukemias or solid non-hematologic tumors, comprising administration of anti-cytokine antibodies or antagonists to inhibit the activity of cytokines which play a role in perpetuating the activation of B cells. The administration of such antibodies and antagonists, particularly anti-IL10 antibodies and antagonists, is particularly useful for avoiding or decreasing the resistance of hematologic malignant cells or solid tumor cells to chemotherapeutic agents and anti-CD20 or anti-CD22 antibodies. The invention also provides combination therapies for solid tumors having B cell involvement comprising the administration of an anti-cytokine antibody and a B cell depleting antibody such as RITUXAN(R).

Owner:BIOGEN INC

Immunoregulatory antibodies and uses thereof

InactiveUS20030103971A1Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsCD37CD23

A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration.

Immunoregulatory antibodies and uses thereof

View all

Owner:BIOGEN INC

Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions

InactiveUS7973043B2Preventing disease progression/modifyingDelaying/preventing relapseBiocideNervous disorderInitial treatmentTherapy resistant

The present invention relates to a new method of treatment for persons meeting diagnoses for major depressive disorder, or other unipolar (non-bipolar, non-psychotic and non-treatment resistant) depression. The method comprises administering a combination of two categories of drugs, antipsychotics or dopamine system stabilizers, in combination with a newer antidepressant such as a selective serotonin reuptake inhibitor, as initial treatment or as soon as possible. The method targets the prevention of suicide, and provides other benefits including preventing disease progression development of tolerance toward the antidepressants. Another aspect of the invention relates to using the method for alleviating cognitive distortion and related functional impairment or health risks, and / or using the method for smoking cessation or nicotine withdrawal.

Owner:MIGALY PETER

Method and system for combined energy therapy profile

ActiveUS20080221491A1Increase temperatureLess energy useUltrasonic/sonic/infrasonic diagnosticsUltrasound therapyEffective treatmentEnergy Therapy

A method and system for treating tissue with a combined therapy profile is disclosed. In one exemplary embodiment, ultrasound energy is used to treat numerous depths of tissue within a region of interest and the spatial and temporal properties of the ultrasound energy are varied for more effective treatment. The method and system of the present invention are configured to treat all of the tissue from the surface on down and not spare intervening tissue.

View all

Owner:GUIDED THERAPY SYSTEMS LLC

Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma

InactiveUS6896885B2Avoiding and decreasing and resistanceIncrease ratingsOrganic active ingredientsIn-vivo radioactive preparationsBiological activationHematologic malignancy

The present invention discloses combined therapies for treating hematologic malignancies, including B cell lymphomas and leukemias or solid non-hematologic tumors, comprising administration of anti-cytokine antibodies or antagonists to inhibit the activity of cytokines which play a role in perpetuating the activation of B cells. The administration of such antibodies and antagonists, particularly anti-IL10 antibodies and antagonists, is particularly useful for avoiding or decreasing the resistance of hematologic malignant cells or solid tumor cells to chemotherapeutic agents and anti-CD20 or anti-CD22 antibodies.The invention also provides combination therapies for solid tumors having B cell involvement comprising the administration of an anti-cytokine antibody and a B cell depleting antibody such as RITUXAN® (rituximab).

Owner:BIOGEN INC

Combinations and modes of administration of therapeutic agents and combination therapy

InactiveUS20070166388A1Heavy metal active ingredientsOrganic active ingredientsNanoparticleAnti vegf antibody

The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents (such as an anti-VEGF antibody), or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.

Combinations and modes of administration of therapeutic agents and combination therapy

View all

Owner:ABRAXIS BIOSCI LLC

Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications

InactiveUS20020028178A1Prevent and reduce proliferation of cellReduce and prevent proliferationRadioactive preparation carriersImmunoglobulins against cell receptors/antigens/surface-determinantsCD20Antiendomysial antibodies

View all

Owner:BIOGEN MA INC

Combination therapy using active immunotherapy

InactiveUS20090004213A1Organic active ingredientsCancer antigen ingredientsSunitinib malateMajor histocompatibility

The present invention relates to methods of treating cancer in a mammal comprising administering to the mammal a combination therapy comprising a vaccine and a multi-kinase inhibitor, wherein the vaccine comprises an isolated tumor associated peptide having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or class-II. Preferably the multi-kinase inhibitor is sunitinib malate and / or sorafenib tosylate or a pharmaceutically acceptable salt thereof.

Combination therapy using active immunotherapy

View all

Owner:IMMATICS BIOTECHNOLOGIES GMBH

Combination treatment of cd38-expressing tumors

ActiveUS20100092489A1Good curative effectImprove survivalBoron compound active ingredientsSkeletal disorderAntiendomysial antibodiesOncology

The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non- corticosteroid chemotherapeutic agent.

Combination treatment of cd38-expressing tumors

View all

Owner:GENMAB AS

Combination therapy for depression

InactiveUS20090023744A1Good curative effectEliminate side effectsOrganic active ingredientsNervous disorderSerotoninMetabolite

A combination therapy for treating depressive disorders is provided herein. The combination therapy comprises administering an effective amount of bupropion or its metabolites together with at least one serotonin 5-HT1A partial agonist or its metabolites to a patient in need of treatment of the depressive disorder. Pharmaceutical formulations, including packaged pharmaceutical formulations, comprising this combination are also provided herein.

Owner:THE GENERAL HOSPITAL CORP

Combination therapy for treating, preventing or managing proliferative disorders and cancers

InactiveUS20040067953A1Improve efficiencyImprove toleranceBiocideHeavy metal active ingredientsCancer preventionBiologically-Based Therapy

The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more inhibitors of JNK in combination with the administration of an effective amount of one or more other agents useful for cancer therapy. The invention also provides pharmaceutical compositions comprising one or more inhibitors of JNK in combination with one or more other agents useful for cancer therapy. In particular, the invention is directed to methods of treatment and prevention of cancer by the administration of an effective amount of one or more inhibitors of JNK in combination with standard and experimental chemotherapies, hormonal therapies, bone marrow transplants, stem cell replacement therapies, biological therapies / immunotherapies and / or radiation therapies for treatment or prevention of cancer. Also included are methods of treatment of cancer by the administration of one or more inhibitors of JNK in combination with surgery, alone or in further combination with standard and experimental chemotherapies, hormonal therapies, bone marrow transplants, stem cell replacement therapies, biological therapies / immunotherapies and / or radiation therapies.

Combination therapy for treating, preventing or managing proliferative disorders and cancers

View all

Owner:SIGNAL PHARMA LLC

Anti-integrin immunoconjugates, methods and uses

InactiveUS20060127407A1Effective rate of releaseSenses disorderAntipyreticDiseaseCytotoxicity

The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.

Anti-integrin immunoconjugates, methods and uses

View all

Owner:IMMUNOGEN INC +1

Method and system for combined energy therapy profile

ActiveUS9011336B2Increase temperatureAvoid prolonged useUltrasonic/sonic/infrasonic diagnosticsUltrasound therapyEffective treatmentEnergy Therapy

View all

Owner:GUIDED THERAPY SYSTEMS LLC

Combination therapy with c-met and her antagonists

InactiveUS20090226455A1Significant anti-tumor activityFacilitates heterodimerizationAntibody ingredientsImmunoglobulinsC-MetFactor ii

The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to combination therapies for the treatment of pathological conditions, such as cancer.

Combination therapy with c-met and her antagonists

View all

Owner:GENENTECH INC

Combination therapy for the treatment of cancer

ActiveUS20070117809A1BiocideAnimal repellantsCombination therapyCancer research

The present invention provides methods of treating cancer comprising treating a patient in need thereof with hormone therapy and administering to the patient a therapeutically effective amount of at least one metalloprotease inhibitor. The present invention also provides pharmaceutical compositions comprising a therapeutically effective amount of at least one hormone therapy agent, at least one metalloprotease inhibitor, and a pharmaceutically acceptable carrier.

Combination therapy for the treatment of cancer

View all

Owner:INCYTE HLDG CORP

Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies

InactiveUS20020197262A1Good curative effectEasy to optimizeElectrotherapyHybrid immunoglobulinsAntiendomysial antibodiesOncology

The present invention relates to photosensitizer immunoconjugate compositions and combination therapies for use in cancer related photodynamic treatments and diagnostic methods. Photosensitizer immunoconjugates comprising a photosensitizer conjugated to a tumor-specific and / or tumoricidial antibody and processes for the preparation thereof are described. The use of photosensitizer immunoconjugates (PICs) offers improved photosensitizer delivery specificity for diagnostic and therapeutic applications. Combination therapies to co-localize activated photosensitizer compounds and tumoricidal antibodies in tumor tissues are also described.

Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies

View all

Owner:THE GENERAL HOSPITAL CORP

Combinations and modes of administration of therapeutic agents and combination therapy

InactiveUS20120128732A1Suppress taxane-mediated upregulationSuppress taxane-mediated upregulation of TNF-aPowder deliveryBiocideDiseaseNanoparticle

The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include the administration of an effective amount of at least one other agent that inhibits a pro survival and/or inflammatory signal.

View all

Owner:ABRAXIS BIOSCI LLC

Anti-Ctla-4 Antibody and Cpg-Motif-Containing Synthetic Oligodeoxynucleotide Combination Therapy for Cancer Treatment

InactiveUS20090117132A1Improve immune activityReducing cytotoxic side effectAntibody ingredientsAntineoplastic agentsThird-line therapyPhases of clinical research

The invention relates to administration of an anti-CTLA-4 antibody, particularly human antibodies to human CTLA-4, such as those having amino acid sequences of antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and MDX-010, in combination with an immunostimulatory nucleotide, i.e, CpG ODN PF3512676, for treatment of cancer. The invention relates to administering a combination of an anti-CTLA-4 antibody and CpG ODN PF3512676 as neoadjuvant, adjuvant, first-line, second-line, and third-line therapy of cancer, whether localized or metastasized, and at any point(s) along the disease continuum (e.g, at any stage of the cancer).